At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 45 enrolled
Drug / intervention
750 mg Imsidolimab +2 moredrug
Likely dose
750 mg Imsidolimabfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Adult Subjects With Generalized Pustular Psoriasis
In Brief
A Phase 3 clinical trial evaluating 750 mg Imsidolimab, 300 mg Imsidolimab, and 1 other intervention for Generalized Pustular Psoriasis. Completed, enrolled 45 participants across 65 sites in 15 countries.
Detailed Summary
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of imsidolimab compared with placebo in adult subjects with generalized pustular psoriasis (GPP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGeneralized Pustular Psoriasis
CountriesAustralia, France, Georgia, Germany, Malaysia, Morocco, Poland, Romania, South Korea, Spain, Taiwan, Thailand, Tunisia, Turkey (Türkiye), United States
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
Enrollment StartApr 2022
First PostedApr 2022
Primary CompletionAug 2023
TodayJul 2026
First PostedApr 29, 2022
Enrollment StartApr 14, 2022
Primary CompletionAug 17, 2023
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 4.2 years ago
Interventions
750 mg Imsidolimabdrug
Intravenous
300 mg Imsidolimabdrug
Intravenous
Placeboother
Intravenous